Role evidence
Usage summary
Strongest role: Inclusion Required
Inclusion-required count: 8
Treatment-assignment count: 0
Stratification count: 0
Trial Selection Rising
ALK fusion
ovarian cancer · Therapy Not Normalized
ALK fusion is flagged as trial selection rising because public trials show inclusion required evidence in 9 contexts. FDA CDx context should be reviewed manually.
Threshold snippets
Fragmentation view
Threshold count: 0
Common snippets: None extracted
Threshold label: Low
FDA CDx context
Mapping summary
CDx label: Fda Cdx Context Manual Review Required
CDx maturity score: 2/5
Confidence: High
Patent-density signal
Diagnostic appendix
Signal count: 0
Recent signals: 0
Density label: Low
Source links
Evidence paths
https://clinicaltrials.gov/study/NCT01199263 | https://clinicaltrials.gov/study/NCT01118052 | https://clinicaltrials.gov/study/NCT01716715 | https://clinicaltrials.gov/study/NCT00058552 | https://clinicaltrials.gov/study/NCT00951496 | https://clinicaltrials.gov/study/NCT01609556 | https://clinicaltrials.gov/study/NCT03180307 | https://clinicaltrials.gov/study/NCT02317705 | https://clinicaltrials.gov/study/NCT07469202